Format

Send to

Choose Destination
Am J Ophthalmol. 2004 Aug;138(2):289-91.

Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease.

Author information

1
Istanbul Retina Institute, Istanbul, Turkey. retina@pobox.com

Abstract

PURPOSE:

To evaluate the safety and effectiveness of intravitreal triamcinolone acetonide in patients with cystoid macular edema (CME) associated with Behçet disease.

DESIGN:

Interventional case series.

METHODS:

Ten eyes of 10 patients with CME from Behçet disease made up the study population. All eyes had persistent CME despite medical treatment for at least 2 months. Intravitreal injection of 4 mg (0.1 ml) of triamcinolone acetonide was offered to treat macular edema. The visual and anatomic responses were observed.

RESULTS:

At 1-month follow-up, a reduction in mean foveal thickness of 37.4%, from 416 microm to 260.5 microm, was attained. At 3-month follow-up, mean foveal thickness was 286.2 microm and at 6 months, 263.7 microm. No eyes had lost vision at 1 month, and eight eyes (80%) showed improvement in visual acuity. At 3-month and 6-month follow-up, three eyes (30%) remained stable and the other eyes had maintained the improved acuity.

CONCLUSION:

Intravitreal triamcinolone acetonide is a promising therapeutic method for CME from Behçet disease.

PMID:
15289142
DOI:
10.1016/j.ajo.2004.02.053
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center